Navigation Links
Cimzia® (certolizumab pegol) Data Showed Broad and Rapid Relief From Burden of Symptoms In Rheumatoid Arthritis Patients
Date:5/10/2011

BRUSSELS, May 10, 2011 /PRNewswire/ -- UCB announced results from a post hoc analysis of the RAPID 2 study, published in the Annals of Rheumatic Diseases, which showed Cimzia®, the only approved PEGylated anti-TNF, plus methotrexate (MTX) provided rapid relief from a broad range of symptoms associated with the burden of moderate to severe active rheumatoid arthritis (RA). Those adult patients treated with Cimzia® that achieved early responses were found to have an increased chance of achieving longer-term outcomes.  

''These data show that when administered with methotrexate, certolizumab pegol offers rapid relief across a broad range of rheumatoid arthritis symptoms and that relatively few patients need to be treated before at least one patient reports clinical benefits from the positive relief the treatment provides,'' said lead investigator Dr. Vibeke Strand, Adjunct Clinical Professor in the Division of Immunology and Rheumatology, at Stanford University, California. ''By assessing patient-reported outcomes at early-stages of treatment we are able to predict late-stage clinical outcomes and treatment benefits for patients, providing great reassurance to both patients and their healthcare professionals.''

PROs were secondary efficacy endpoints in RAPID 2 and were used to measure the impact of treatment with certolizumab pegol versus placebo. Number needed to treat (NNT) analysis was used in these post hoc analyses to interpret the PRO results. The NNT determines the number of patients that need to be treated in order to obtain the benefit of interest in one additional patient; therefore, small NNTs indicate favorable treatment effects. NNTs and minimum clinically important differences (MCIDs, which determine clinically meaningful improvements) were evaluated.

In the RAPID 2 study, patients with active RA (by 1987 American College of Rheumatology [ACR] classification criteria) with inadequate responses to MTX th
'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA)
2. Rapid and Long-term Clinical Responses Observed in Rheumatoid Arthritis Patients Taking Cimzia® (certolizumab pegol), According to Data Being Highlighted During ACR Meeting
3. UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohns Disease
4. Long-Term Data on Cimzia® (certolizumab pegol) for Moderate to Severe Crohns Disease to be Highlighted at ACG Meeting
5. New Data Show CIMZIA(R) (certolizumab pegol) Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients
6. CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years
7. CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohns Disease Patients
8. CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohns Patients
9. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
10. New Subanalyses of the RE-LY Trial Showed Pradaxa Reduced Stroke Risk in Patients With Varying CHA2DS2-VASc Scores and Types of Non-Valvular Atrial Fibrillation
11. Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Five Years of Treatment With Similar Safety Profile Observed in Pivotal Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... TAIPEI , 1. September 2015 ... Marksteins von 2.500 Mitarbeitern hat die SHL Group ... ein konstantes und rapides Wachstum auf dem ... Engagement, die Produktivität und das Management von SHL ... SHL ist weltweit führend in Design ...
(Date:9/1/2015)... Sept. 1, 2015 Pressure BioSciences, Inc. ... in the development and sale of broadly enabling, ... the worldwide life sciences industry, today announced the ... the Company,s PCT Platform could play a significant ... This role is based on PCT,s unique ability ...
(Date:9/1/2015)... VIEW, Calif. , Sept. 1, 2015 ... the cardiovascular image management market, Frost & ... the 2015 European Frost & Sullivan Award ... -based PMI has designed innovative and ... lines—which deliver precise and reproducible quantitative results ...
Breaking Medicine Technology:SHL Group erreicht wichtigen Markstein von 3.000 Mitarbeitern 2New Scientific Publication Suggests Pressure BioSciences' PCT Platform Could Play Significant Role in Personalized/Precision Medicine 2New Scientific Publication Suggests Pressure BioSciences' PCT Platform Could Play Significant Role in Personalized/Precision Medicine 3New Scientific Publication Suggests Pressure BioSciences' PCT Platform Could Play Significant Role in Personalized/Precision Medicine 4New Scientific Publication Suggests Pressure BioSciences' PCT Platform Could Play Significant Role in Personalized/Precision Medicine 5Frost & Sullivan Applauds Pie Medical Imaging for Highly Innovative Quantitative Software for Cardiovascular Diagnosis 2Frost & Sullivan Applauds Pie Medical Imaging for Highly Innovative Quantitative Software for Cardiovascular Diagnosis 3Frost & Sullivan Applauds Pie Medical Imaging for Highly Innovative Quantitative Software for Cardiovascular Diagnosis 4Frost & Sullivan Applauds Pie Medical Imaging for Highly Innovative Quantitative Software for Cardiovascular Diagnosis 5
... Second generation,pyridopyrazine-urea derivative compound series show highly,selective ... , , QUBEC CITY, Canada, April,16, ... Nasdaq:,AEZS), a global, pure play biopharmaceutical company ... an abstract,outlining first in vitro data on ...
... Activity as Vascular Disrupting Agent and,Tubulin Inhibitor ... 2007—Myriad Genetics, Inc.,(NASDAQ: MYGN) (<a target="_blank" href=,"http://www.myriad.com/">www.myriad.com ... characterize the mode of action of its,investigational ... at the annual meeting of the American ...
Cached Medicine Technology:terna Zentaris Discloses First In Vitro Data for its PI3K,Inhibitors at the AACR Annual Meeting in Los Angeles 2terna Zentaris Discloses First In Vitro Data for its PI3K,Inhibitors at the AACR Annual Meeting in Los Angeles 3terna Zentaris Discloses First In Vitro Data for its PI3K,Inhibitors at the AACR Annual Meeting in Los Angeles 4Myriad Genetics Presents Azixa's Mode of Action at AACR 2Myriad Genetics Presents Azixa's Mode of Action at AACR 3
(Date:9/1/2015)... Fairfax, VA (PRWEB) , ... September 01, 2015 ... ... the Mane Vendor “Hair Extension Vending Machine,” is still strongly maintaining her firm’s ... modern technology, and beauty tools. In her upcoming city-to-city tour, Ellis will be ...
(Date:9/1/2015)... ... September 01, 2015 , ... The ... Information Management has been granted continued accreditation based on a successfully completed ... “Achieving and maintaining this accreditation takes the involvement and dedication of each ...
(Date:9/1/2015)... ... 01, 2015 , ... With former IBMers among its founding members, Inmar has ... more than 35 years ago. A pilot program begun by the company in 2014 ... just those intent on pursuing careers in these fields. The program is now open ...
(Date:9/1/2015)... , ... September 01, 2015 , ... Royal River Natural ... study that followed men and women for 19 years and found that, among those ... not take multivitamins. , The report is part of the September 2015 issue of ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... The ... and incurable disease, facioscapulohumeral muscular dystrophy (FSHD), will be the beneficiary of a collection ... same mission – to raise awareness of the FSH Society and further FSHD research. ...
Breaking Medicine News(10 mins):Health News:Beauty Entrepreneur creates hair extension smart machine and mobile app inspired by UBER technology 2Health News:Edge Information Management Granted Continued NAPBS Accreditation 2Health News:Edge Information Management Granted Continued NAPBS Accreditation 3Health News:Inmar Announces Program to Fuel Student Passion for STEM – with an Unconventional Twist 2Health News:New Study Finds Multivitamins Extend Life After Stroke, Retailer Reports 2Health News:FSH Society Beneficiary of Variety of Fall Fundraising Events 2Health News:FSH Society Beneficiary of Variety of Fall Fundraising Events 3
... Feb. 24 drugstore.com , inc. (Nasdaq: ... of health, beauty, vision, and pharmacy products, today ... be presenting at the upcoming Jefferies 5th Annual ... drugstore.com(TM) presentation will take place on Thursday, February ...
... 24 PolyRemedy, Inc., a,manufacturer of point-of-care robotic ... wound treatments, has hired Jeffrey S.,Jones to serve ... Jones, a,seasoned healthcare executive, joined the PolyRemedy management ... "With his experience in growing innovative medical device ...
... New guidelines suggest that men discuss use of medicines such ... News) -- Healthy men with no signs of prostate cancer ... drug that could further reduce their risk for the disease, ... Oncology and the American Urological Association have issued new guidelines ...
... danger, large study finds, , , TUESDAY, Feb. 24 (HealthDay News) ... that even moderate drinking raises risks for breast, liver and ... on the order of one alcoholic drink per day -- ... Naomi Allen, from the cancer epidemiology unit at the University ...
... would Lower the Standard of Care by Allowing ... Anesthesia to Maryland PatientsANNAPOLIS, Md., Feb. 24 ... members are Certified Registered Nurse Anesthetists (CRNAs), today ... House Bill 1161. These troubling bills would ...
... RIVER EDGE, N.J., Feb. 24 ... device company developing and marketing filtration products for ... reported that is has received initial responses from ... for dialysis devices. 510k Application for OLpur ...
Cached Medicine News:Health News:drugstore.com, inc. to Present at the Upcoming Jefferies 5th Annual Internet & Media Conference 2Health News:PolyRemedy Names Jeffrey Jones as Its Chief Operating Officer 2Health News:Drugs May Help Healthy Men Lower Prostate Cancer Risk 2Health News:Drinking Raises Cancer Risk for Middle-Age Women 2Health News:Drinking Raises Cancer Risk for Middle-Age Women 3Health News:New Anesthesia Provider May Threaten Operating Room Safety 2Health News:New Anesthesia Provider May Threaten Operating Room Safety 3Health News:New Anesthesia Provider May Threaten Operating Room Safety 4Health News:Nephros Provides Update on 510k Applications 2Health News:Nephros Provides Update on 510k Applications 3Health News:Nephros Provides Update on 510k Applications 4
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: